Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.